Lipoproteína(a)
Grupo Argentino Estudio Lipoproteína (a)
.png)
Novedades Abril 2026
PLoS One. 2026 Feb 23;21(2):e0342704. doi: 10.1371/journal.pone.0342704. eCollection 2026.
Autores:
Mengru Wang 1 , Fudong Hu 2 , Rongyan Jiang 1 , Sheng Tu 1
Conclusión: The Lp(a)-CatLet© synergy enhances MACCE risk stratification in ePCI-treated AMI, reflecting complementary pathobiological (Lp(a)-driven plaque vulnerability) and anatomical (CatLet©-quantified complexity) pathways. This dual-parameter approach could support post-PCI risk stratification and follow-up planning.
Cardiol J. 2026:33:e00226010. doi: 10.5603/cj.108082. Epub 2025 Oct 16.
Autores:
Tomasz Saniewski 1 2 , Grzegorz Procyk 3 4 , Jakub Zimodro 3 4 , Olivia Wasilewska 5 , Bartosz Mroczyk 5 , Michał Lis 5 6 , Aleksandra Gąsecka 3
Conclusión: High Lp(a) is prevalent in the Polish population, and thus it is important to measure it routinely in each individual at least once in a lifetime and control all other known cardiovascular risk factors to decrease the overall risk.
Curr Opin Lipidol. 2026 Apr 1;37(2):65-72. doi: 10.1097/MOL.0000000000001030. Epub 2026 Feb 6.
Autores:
Stefan Coassin 1
Conclusión: Technological advances establish a foundation for more accurate genetic risk assessment across ancestries. These advances are enhancing our understanding of Lp(a) regulation and build a framework for future integrative genetic studies, which may shed new light on the evolution of the Lp(a) trait, adding important context for its physiological and clinical relevance.
Curr Opin Lipidol. 2026 Apr 1;37(2):58-64. doi: 10.1097/MOL.0000000000001024. Epub 2026 Jan 28.
Autores:
Arya Aminorroaya 1 2 , Rohan Khera 1 2 3 4 5
Conclusión: Machine learning-based strategies provide a scalable means of operationalizing universal Lp(a) testing recommendations within health systems. When developed using unbiased data, externally validated, and assessed for fairness and interpretability, these models can support systematic identification of individuals with elevated Lp(a) and integration of Lp(a) measurement into routine cardiovascular risk assessment.
J Clin Lipidol. 2026 Feb;20(2):317-325. doi: 10.1016/j.jacl.2025.12.002. Epub 2025 Dec 4.
Autores:
Shoshana H Bardach 1 , Skye Chernichky-Karcher 2 , Allison Hawke 3 , Diane MacDougall 3 , Katherine Wilemon 3 , Laurence S Sperling 4
Conclusión: This analysis highlights that Lp(a) testing decisions are multifactorial, providing multiple opportunities for intervention and improvement. Strategies to convey how Lp(a) measurement can inform risk assessment and treatment approaches may be foundational to encouraging more widespread testing.
Am J Med Sci. 2026 Mar;371(3):274-280. doi: 10.1016/j.amjms.2025.09.009. Epub 2025 Dec 21.
Autores:
Brian Brereton 1 , Rupak Desai 2 , Pratiksha Shankarlal Nathani 3 , Shisheer Havangi Prakash 4 , Amritha Nair 5 , Chantal Lewis 6 , Amreen Sidhu 7 , Sadiya Usman 8 , Shaylika Chauhan 9 , Vinutha Akki Vivekanand 10 , Athmananda Nanjundappa 11 , Praveena Sunkara 12
Conclusión: There is some evidence that Lp (a) levels are an independent risk factor for MACE in patients who underwent PCI for CAD. There is also some evidence that elevated Lp (a) levels are associated with a worse prognosis in patients with DM after PCI, but this association is not consistent in the literature. Further prospective multicenter studies are required in order to elucidate this association.
Clin Investig Arterioscler. 2026 Mar-Apr;38(2):500870. doi: 10.1016/j.arteri.2025.500870. Epub 2025 Oct 18.
Autores:
Rosa Fernández-Olmo 1 , Jesús Lara Mariscal 2 , Ana García Ruano 3 , Alberto Cordero 4 , Juan Manuel Castillo Casas 5 , Diego Franco 5
Minerva Cardiol Angiol. 2026 Feb;74(1):128-134. doi: 10.23736/S2724-5683.24.06534-7. Epub 2024 Jun 5.
Autores:
Gianmarco Cancelli 1 , Lamia Harik 1 , Mudathir Ibrahim 2 , Irbaz Hameed 3 , Camilla Rossi 1 , Tulio Caldonazo 1 , Michele Dell'aquila 1 , Giovanni J Soletti 1 , Kevin R An 1 , Jordan Leith 1 , Michelle Demetres 4 , Arnaldo Dimagli 1 , Mario F Gaudino 5
Conclusión: Studies evaluating the impact of Lp(a) on outcomes in CABG patients are few, with heterogenous cut-offs and outcomes. In the limited published studies, Lp(a) level was not associated with graft occlusion.
J Assoc Physicians India. 2026 Feb;74(2):33-37. doi: 10.59556/japi.74.1331.
Autores:
Sonali Sharma 1 , Ramesh Kumar Chandak 2 , Krishna Kumar Sharma 3 , Soneil Guptha 4 , Rajeev Gupta 5
Conclusión: Substantial variation in coronary artery disease (CAD) risk prediction using various clinical algorithms is observed in T2D. The EAS algorithm provides the most robust estimate. The addition of Lp(a) to the risk algorithms augments risk stratification significantly. The results of this pilot study need confirmation with larger prospective studies.
Pharmacol Ther. 2026 May:281:109010. doi: 10.1016/j.pharmthera.2026.109010. Epub 2026 Feb 20.
Autores:
Elias Björnson 1 , Chris J Packard 2 , Jan Borén 3
Am J Med Sci. 2026 Apr;371(4):336-344. doi: 10.1016/j.amjms.2025.12.002. Epub 2025 Dec 5.
Autores:
Yan-Yan Li 1 , Hui Wang 2 , Yang-Yang Zhang 3
Conclusión: LPA rs3798220 and rs10455872 polymorphisms were significantly associated with increased CAD risk. The persons carrying C allele of LPA rs3798220 and G allele of LPA rs10455872 polymorphisms might have higher CHD risk than the T allele of rs3798220 or A allele of rs10455872 carriers.
Lipids. 2026 Mar;61(2):265-274. doi: 10.1002/lipd.70025. Epub 2025 Nov 30.
Autores:
Clara M Howell 1 , Liv Hald Nyhave 1 , Bent Raungaard 1 2 , Aase Handberg 1 3 , Claus Gyrup Nielsen 3 , Christian Bork 1 2 , Stine Krogh Venø 1 3
Lakartidningen. 2026 Mar 20:123:25150.
Autores:
Elias Björnson 1 , Jonas Brinck 2 , Emil Hagström 3 , Jan Borén 4
Circ Popul Health Outcomes. 2026 Mar;19(3):e013261. doi: 10.1161/CIRCOUTCOMES.125.013261. Epub 2026 Feb 20.
Autores:
Ashkan Abdollahi 1 2 , Aysa Ostovaneh 2 , Omar Chehab 2 , Malak Hoballah 2 , Bruna R S Matuck 2 , Colin O Wu 3 , Seamus P Whelton 4 , Bharath Ambale-Venkatesh 5 , Wendy S Post 2 , David A Bluemke 6 , Michael Y Tsai 7 , Sotirios Tsimikas 8 9 , João A C Lima 2 5
Conclusión: Elevated Lp(a) levels were independently associated with maladaptive left ventricular and left atrial remodeling in Hispanic adults over a decade, while no statistically significant relationships were observed in White, Black, and Chinese participants. This suggests a unique susceptibility of Hispanic individuals to Lp(a)-mediated cardiovascular remodeling, independent of ischemic pathways.
J Clin Lipidol. 2026 Mar;20(3):671-676. doi: 10.1016/j.jacl.2026.01.018. Epub 2026 Jan 27.
Autores:
Jadry Gruen 1 , Archna Bajaj 2
Conclusión: Ahead of results from ongoing clinical trials testing Lp(a)-targeted therapies, health systems can use QI methods to assess current Lp(a) ordering practices, identify patients who may benefit from future Lp(a)-targeted therapy, and plan for rapid expansion of Lp(a) testing.
J Clin Lipidol. 2026 Mar;20(3):600-608. doi: 10.1016/j.jacl.2026.01.015. Epub 2026 Jan 27.
Autores:
Matteo Paolucci 1 , Giacomo Urbinati 2 , Mauro Gentile 1 , Stefano Forlivesi 1 , Giorgia Arnone 1 , Ludovica Migliaccio 1 , Maria Maddalena Viola 1 , Simone Galluzzo 3 , Cristiano Fanciulli 2 , Mario Sebastiani 1 , Eric Ramazzotti 4 , Rita Mancini 4 , Luigi Simonetti 3 , Andrea Zini 5
Conclusión: Higher Lp(a) values are associated with LAA stroke, particularly ICAS. Lp(a) levels should be included in the stroke workup.
Curr Med Res Opin. 2026 Jan;42(1):19-24. doi: 10.1080/03007995.2026.2627735. Epub 2026 Feb 11.
Autores:
Andreas Tridimas 1 2 , Suha Ahmed 3
Conclusión: Routine Lp(a) testing meaningfully alters management and reveals a form of residual dyslipidaemia resistant to standard therapy. These findings, combined with recent cost-effectiveness modelling showing NHS and societal savings from one-time testing, support incorporation of Lp(a) measurement into universal cardiovascular risk assessment.
J Clin Lipidol. 2026 Mar;20(3):609-619. doi: 10.1016/j.jacl.2025.12.016. Epub 2025 Dec 23.
Autores:
Dimitrios Delialis 1 , Polyxeni Manifava 1 , Sofia-Panagiota Giannakopoulou 2 , Christina Konstantaki 1 , Stavros Athanasopoulos 1 , Georgios Zervas 1 , Panagiotis Nastatos 1 , Georgios Mavraganis 1 , Kateryna Sopova 3 , Maria-Angeliki Dimopoulou 1 , Lydia Kokkinidou 1 , Yannis Skoumas 4 , Christos Pitsavos 4 , Nikolaos Rachiotis 1 , Lasthenis Angelidakis 1 , Dimitrios Papoutsis 1 , Peggy Kostakou 1 , Elisabeth Samouilidou 5 , Achilleas A Zacharoulis 6 , Konstantinos Stellos 7 , Evangellos Liberopoulos 8 , Christina Chrysochoou 4 , Georgios Georgiopoulos 1 , Demosthenes Panagiotakos 2 , Kimon Stamatelopoulos 9
Conclusión: Elevated Lp(a) levels were observed in 8.3% of the general population cohort and up to 23.9% in participants with ASCVD from the lipid clinic cohort, highlighting a risk gradient across ASCVD categories. Incorporating Lp(a) as a risk enhancer improves ASCVD risk reclassification beyond the validated HellenicSCOREII+.
Diabetes Obes Metab. 2026 Apr;28(4):3044-3053. doi: 10.1111/dom.70491. Epub 2026 Jan 21.
Autores:
Zenglei Zhang 1 , Lin Zhao 2 , Zeyu Wang 1 , Xianliang Zhou 1 , Xianlun Li 2 , Weixian Yang 1 , Xu Meng 1
Conclusión: Elevated Lp(a) levels were associated with a higher risk of ASCVD across different glucose metabolism statuses, particularly among individuals with NGR and prediabetes, independent of baseline CRP levels.
Georgian Med News. 2025 Dec:(369):120-126.
Autores:
G Derbissalina 1 , Z Bekbergenova 1 , A Umbetzhanova 1 , G Mauletbayeva 1 , G Bedelbayeva 2
Conclusión: Comprehensive assessment of anthropometric and biochemical biomarkers may be useful for early cardiovascular risk stratification in patients with arterial hypertension in Kazakhstan. The observed tendencies highlight potential region-specific features of cardiometabolic risk, warranting further investigation in larger cohorts.
Int J Mol Sci. 2026 Jan 23;27(3):1160. doi: 10.3390/ijms27031160.
Autores:
Agnė Liuizė Abramavičiūtė 1 , Jolanta Laukaitienė 1 , Renata Paukštaitienė 2 , Viltė Marija Gintauskienė 3 , Aušra Mongirdienė 1
JAMA Cardiol. 2026 Feb 1;11(2):175-185. doi: 10.1001/jamacardio.2025.5043.
Autores:
Ask Tybjærg Nordestgaard 1 2 , Daniel I Chasman 1 3 , Vinayaga Moorthy 1 , Jordan M Kraaijenhof 4 , Nancy R Cook 1 3 , I-Min Lee 1 3 , Julie E Buring 1 3 , Paul M Ridker 1 3 5
Conclusión y Relevancia: Per the results of this cohort study, very high lipoprotein(a) levels correlated with increased 30-year risk of cardiovascular disease among healthy women. Screening for elevated lipoprotein(a) in the general population may be warranted.
Eur Heart J Cardiovasc Imaging. 2026 Feb 9;27(2):264-273. doi: 10.1093/ehjci/jeaf320.
Autores:
Marin Boute 1 2 , Paul Salembier 1 2 , Anne-Catherine Pouleur 1 2 , Agnès Pasquet 1 2 , Bernhard L Gerber 1 2 , David De Azevedo 1 2 , Damien Gruson 2 3 , Laurent de Kerchove 2 4 , Joelle Kefer 1 2 , Christophe Beauloye 1 2 5 , Sandrine Horman 2 , Frédéric Maes 1 2 , Sophie Pierard 1 2 5 , David Vancraeynest 1 2
Conclusión: Elevated Lp(a) is independently associated with long-term risk of stenotic/mixed SVD. These findings highlight Lp(a) as a promising biomarker of prosthetic valve vulnerability and support investigation of emerging Lp(a)-lowering therapies to improve valve durability.
J Card Fail. 2026 Feb;32(2):382-390. doi: 10.1016/j.cardfail.2025.03.016. Epub 2025 Apr 4.
Autores:
Adithya K Yadalam 1 , Apoorva Gangavelli 2 , Alexander C Razavi 1 , Yi-An Ko 3 , Ayman Alkhoder 1 , Nisreen Haroun 1 , Rafia Lodhi 1 , Ahmed Eldaidamouni 1 , Mahmoud Al Kasem 1 , Arshed A Quyyumi 4
Conclusión: In patients with HF, Lp(a) ≥30 mg/dL independently predicts the risk of cardiovascular death or HF hospitalization.
J Am Heart Assoc. 2026 Feb 17;15(4):e042361. doi: 10.1161/JAHA.125.042361. Epub 2026 Feb 11.
Autores:
Richard Kazibwe 1 , Christopher L Schaich 2 , Parag A Chevli 3 , Jeff A Kingsley 3 , Saeid Mirzai 3 , Juliana H Namutebi 4 , Muhammad Imtiaz Ahmad 5 , Anurag Mehta 6 , Harpreet S Bhatia 7 , Mitchell Paukner 8 , Rishi Rikhi 9 , Erin D Michos 10 , Michael D Shapiro 11
Conclusión: Lp(a) and IR each independently contribute to cardiovascular risk, with a combination offering improved risk stratification. This suggests that accounting for IR may enhance the assessment of Lp(a)-associated risk in the context of primary CVD prevention setting.
Turk Kardiyol Dern Ars. 2026 Feb 20;54(2):101-108. doi: 10.5543/tkda.2026.07748. Epub 2026 Jan 23.
Autores:
Ece Yurtseven 1 , Dilek Ural 1 , Gizem Yaşa 2 , Berk Kabadayı 2 , Özgür Özdemir 2 , Erol Gürsoy 1 , Saide Aytekin 1 , Vedat Aytekin 1 , Meral Kayikcioglu 3
Conclusión: In statin-naïve elderly individuals with elevated LDL-C levels, male sex, cumulative LDL-C exposure, and high Lp(a) levels were independently associated with CAD. These findings underscore the potential utility of incorporating cumulative LDL-C and Lp(a) into risk stratification for older adults.
Eur J Prev Cardiol. 2026 Feb 18;33(3):352-360. doi: 10.1093/eurjpc/zwae371.
Autores:
Martin Bird 1 , Antoine Rimbert 2 , Alan Michael Pittman 3 , Steve Eric Humphries 4 , Marta Futema 1 4
Conclusión: This genome-wide analysis of monogenic and polygenic FH causes confirms a complex and heterogeneous architecture of hypercholesterolaemia, with the LPA gene playing a significant role. Both Lp(a) and LDL-C should be measured for precision FH diagnosis. Specific therapies to lower Lp(a) should be targeted to those who will benefit most.